Literature DB >> 10486463

Angiogenesis in cervical intraepithelial neoplasia and the risk of recurrence.

W Tjalma1, H Sonnemans, J Weyler, E Van Marck, A Van Daele, P van Dam.   

Abstract

OBJECTIVE: We sought to investigate whether angiogenesis can predict the risk of recurrence of cervical intraepithelial neoplasia after treatment. STUDY
DESIGN: Microvessel density was studied in 75 patients with grade 3 cervical intraepithelial neoplasia and in 20 patients with microinvasive squamous carcinoma (International Federation of Gynecology and Obstetrics stage IA1) of the uterine cervix by staining representative tissue sections with the specific endothelial marker anti-CD31. The microvessel density was determined with a digital image analyzer. The results were correlated with clinical and histopathologic data.
RESULTS: The mean vessel density was 264 per field (range, 86-674 per field) in grade 3 cervical intraepithelial neoplasia and 378 per field (range, 161-848 per field; P = .001) in microinvasive squamous carcinoma. Thirteen patients with grade 3 cervical intraepithelial neoplasia had recurrent cervical intraepithelial neoplasia (microvessel density, recurrent vs nonrecurrent; not significant). Multiple regression analysis in the noninvasive group confirmed that the mean vessel density (P = .121) had no prognostic value. Furthermore, it showed that the age at diagnosis (P = .011), menopausal status (P = .052), and treatment modality (P = .022) proved to be independent prognostic factors for recurrence.
CONCLUSIONS: During the progression from noninvasive to microinvasive cervical carcinoma, the microvessel density increases significantly. However, the vessel density does not predict recurrence of noninvasive lesions.

Entities:  

Mesh:

Year:  1999        PMID: 10486463     DOI: 10.1016/s0002-9378(99)70492-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

Review 1.  The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.

Authors:  B Woodby; M Scott; J Bodily
Journal:  Prog Mol Biol Transl Sci       Date:  2016-10-11       Impact factor: 3.622

Review 2.  Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer.

Authors:  Lauren S Krill; Krishnansu S Tewari
Journal:  Clin Ther       Date:  2015-01-01       Impact factor: 3.393

3.  Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.

Authors:  Yunhai Chuai; Ivana Rizzuto; Xia Zhang; Ying Li; Guanghai Dai; Sophie J Otter; Rasiah Bharathan; Alexandra Stewart; Aiming Wang
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04

4.  Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions.

Authors:  Liudmyla M Lazarenko; Olena E Nikitina; Evgen V Nikitin; Olga M Demchenko; Galyna V Kovtonyuk; Larysa O Ganova; Rostyslav V Bubnov; Veronika O Shevchuk; Natalia M Nastradina; Viktoria V Bila; Mykola Ya Spivak
Journal:  EPMA J       Date:  2014-01-06       Impact factor: 6.543

Review 5.  Angiogenesis in pre-malignant conditions.

Authors:  S R Menakuru; N J Brown; C A Staton; M W R Reed
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640

6.  In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment.

Authors:  Peter A van Dam; Pieter-Jan H H van Dam; Christian Rolfo; Marco Giallombardo; Christophe van Berckelaer; Xuan Bich Trinh; Sevilay Altintas; Manon Huizing; Kostas Papadimitriou; Wiebren A A Tjalma; Steven van Laere
Journal:  Oncotarget       Date:  2016-01-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.